


1627

TECH CENTER 1600/2900
NOV 13 2001

RECEIVED



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: GARVEY et al

Application No.: 09/478,222

Group Art Unit: 1627

Filed: January 5, 2000

Examiner: B. Celsa

For: Nitrosated and Nitrosylated Alpha-Adrenergic Receptor
Antagonist Compounds, Compositions and Their Uses

Attorney Docket No.: 102258.346

Assistant Commissioner of Patents
Washington, DC 20231#15
10/98
1-21-02INFORMATION DISCLOSURE STATEMENT


Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants bring to the attention of the Examiner the document listed on the attached PTO-1449 Form. A copy of the document is submitted herewith.

The submission of this Information Disclosure Statement does not represent that a search has been made and does not constitute an admission that the listed document is material to patentability or that the listed document is prior art.

This Information Disclosure Statement is being filed after a first office action, but before a final office action or notice of allowance. Accordingly, the Commissioner is authorized to charge the fee of \$180 to Deposit Account No. 08-0219. The Commissioner is authorized to charge any other necessary fees or credit any overpayments to Deposit Account No. 08-0219 to maintain the pendency of the application.

Applicants respectfully request that the Examiner return an initialed copy of the PTO-1440 Form with the next communication from the PTO.

Respectfully submitted,



Edward D. Grieff
Registration No. 38,898

Date: November 7, 2001

HALE and DORR LLP
1455 Pennsylvania Avenue, NW
Washington, DC 20004
Phone: (202) 942-8400